Ожирение и артериальная гипертензия. Часть II: особенности антигипертензивной терапии при ожирении
Аннотация
Обзор посвящен особенностям антигипертензивной терапии (АГТ) при артериальной гипертензии на фоне ожирения. Особое внимание уделяется патогенезу повышения артериального давления при ожирении. Проведен анализ безопасности применения различных классов антигипертензивных препаратов у этой проблемной категории пациентов. Приведены данные о наиболее эффективных режимах АГТ на фоне назначения медикаментозных средств для снижения веса.
Об авторах
С. В. Недогода
Волгоградский государственный медицинский университет
Россия
Россия
И. Н. Барыкина
Волгоградский государственный медицинский университет
Россия
Россия
Т. А. Чаляби
Волгоградский государственный медицинский университет
Россия
Россия
Л. В. Бутрина
Волгоградский государственный медицинский университет
Россия
Россия
У. А. Брель
Волгоградский государственный медицинский университет
Россия
Россия
Г. В. Мазина
Волгоградский государственный медицинский университет
Россия
Россия
Е. А. Подольская
Волгоградский государственный медицинский университет
Россия
Россия
Список литературы
1. Assmaim G, Schulte Н. The Prospective Cardiovascular Munster Study (PROCAM): prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary artery disease. Am Heart J 1989; 1116:1713-24.
2. Basa S, Folliguet T, Anselmo M, et al. Lipomatous hypertrophy of the interatrial Septum. Cardiovasc Surg 1994; 2: 229—30.
3. Bergman RN, Van Citters GW, Mittelman SD, et al. Central role of adipocyte in the metabolic syndrome. J Invest Med 2001; 49: 119-26. "
4. BharatiS, LevM. Cardiac conduction system involvement in sudden death of obese young people. Am Heart J 1995; 129: 273-81.
5. Bloomfield GL, Sugerman HJ, Blocher CR, et al. Chronically increased intra-abdominal pressure produced systemic hypertension in dogs. Inti J Obes Relat Metab Disord 2000; 24: 819-24.
6. Cardillo C, Kilcoyne CM, Camion RO III, Panza JA. Increased activity of endogenous endothelin in patients with hypercholesterolemia. JACC 2000; 36(5): 1483-8.
7. Chu NF, Spiegelman D, Hotamisligil GS, et al. Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrOmbogenic cardiovascular disease factors amongmen. Atherosclerosis 2001; 157:495—503.
8. Cooper R, McFarlane Anderson N, Bennett FI, et al. ACE, angio-tensinogen and obesity: a potential pathway leading to hypertension. J Hum Hypertens 1997; 11: 107-11.
9. Das UN. Is obesity an inflammatory condition? Nutrition 2001; 17:953-66.
10. Davi G, Guagnano МТ, Ciabattoni G, et al. Platelet activation in obese women: role of inflammation and oxidative stress. JAMA 2002; 288: 2008-14.
11. Desideri G, Ferri C. Effects of Obesity and weight loss on soluble CD 40L levels. JAMA 2003; 289:1781-2.
12. Dessi-Fulgheri P, Sarzani R, Serenelli M, et al. Low calorie diet enhances renal, hemodynamic, and humoral effects of exogenous atrial natriuretic peptide in obese hypertensives. Hypertension 1999; 33: 658-62.
13. Drenick EJ, Bale GS, Seltzer F, Johnson DG. Excessive mortality and cause of death in morbidly obese men. JAMA 1980; 243: 443-5.
14. Duflou J, Virmani R, Rabin J, et al. Sudden death as a result of heart disease inmorbid obesity. Am Heart J 1995; 130: 306—13.
15. - Et-Haschimi K, Pierroz DD, Hileman SM, et al. Two defects contribute to hypothalmic leptin resistance in mice with diet-induced obesity. J Clin Invest 2000; 105:1827—32.
16. Esler M. The sympathetic system and hypertension. Am J Hypertens 2000; 13:99S-105.
17. Frolilidi ED, Epstein C, Chobanian AV, et al. The heart in hypertension. N Engl J Med 1992; 327:998-1008.
18. Gorzelniak K, Engeli S, Janke J, et al. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens 2002; 20:1115-20.
19. Granger JP, Wfest D, Scott J Abnormal pressure natriuresis in the dog model of obesity-induced hypertension. Hypertension 1994; 23: 18-11.
20. Grassi G, Seravalle G, Columbo M, et al. Body weight reduction sympathetic nerve traffic and arterial baroreflex in obese normoten-sive humans. Circulation 1998; 97: 2037-42.
21. Gupta AK, Clark RV, Kirclmer KA. Effects of insulin on renal sodium excretion. Hyperfensionl992; 19(Suppl 1); 178—82.
22. Hall JE. Meclianisms of abnormal renal sodium handling in obesity hypertension. Am J Hypertensl997; 10:49S-55.
23. Haynes WG, Morgan DA, Walsh SA, et al. Cardiovascular consequences of obesity: role of leptin. Clin Exp Pharmacol Physiol 1998;25:65-9.
24. Hildebrandt DA, Mizelle HL, Brands MW, Hall JE. Systemic hemodynamic actions of long-term intravertebral angiotensin II infusion. FASEB 1993; 7J: A405.
25. Jacobs DB, Sowers JR, Hmeidan A, et al. Effects of weight reduction on cellular cation metabolism and vascular resistance. Hypertension 1993; 21: 308-14.
26. Kenchaiali S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305-13.
27. Konstantinides S, Schafer K, Loskutoff DJ. The prothrombotic effects of leptin— possible implications for the risk of cardiovascular disease in obesity. Ami NY Acad Sci2001;947: 134-41.
28. Kuo J, Jones OB, Hall JE. Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin. Hypertension 2001;37:670-6.
29. Laasko M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese men. J Clin Invest 1990; 85:1844-52.
30. Lembo G, Vecchione C, Fratta L, et al. Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes 2000; 49: 293-7.
31. Licata G, Scaglione, Capuana G, et al. Hypertension in obese subjects: distinct hypertensive subgroup. J Himi Hypertens 1990; 4: 37-41.
32. Lu H, Duaimiu /. Houck C, et al. Obesity due to high fat diet decreases the sympathetic nervous and cardiovascular responses to intracerebroventricular leptin in rats. Brain Res Bull 1998; 47: 331-5.
33. Mansuo K, Mikami H, Ogiliara T, Tuck ML. Weight gain-induced blood pressure elevation. Hypertension 2000; 35: 1135—40.
34. Masuo K, Mikami H, Ogiliara T, et al. Weight reduction and pharmacologic treatment in obese hypertensives. Am J Hypertens 2001; 14: 530-8.
35. Messerli FH, Simdgard-Riiske K, Reisin E, et al. Dimorphic cardiac adaptation to obesity and arterial hypertension. Ami Intern Med 1998; 99: 757-61.
36. Okosun ISA, Choi S, Dent MM, et al. Abdominal obesity defined as a larger than expected girth is associated with racial/ethnic differences in the risk of hypertension. J Himi Hypertens 2001; 15: 307-12.
37. Reisin E,. Azars S, DeBoisblanc BP, et al. Low calorie unrestricted protein diet attenuates renal injury in hypertensive rats. Hypertension 1993; 21: 971-4.
38. Reisin E, Weir MR, Falkner B, et al. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial: Treatment in Obese Patients with Hypertension (TROPHY) Study Group. Hypertension 1997; 30: 140-5.
39. Resnick LM, Militianu D, Cunnings AJ, et al. Direct magnetic resonance determination of aortic distensibility in essential hypertension, relation to age, abdominal visceral.fat, and in situ intracellular free magnesium. Hypertension 1997; 30: 654—9.
40. Rocchini AP, Mao HZ, Babu K, et al. Clonidine prevents insulin resistance and hypertension in obese dogs. Hypertension 33; 1999: 548-53,
41. Rumantir MS, Vaz M, Jennings GL, et al. Neural meclianisms in human obesity-related hypertension. J Hypertens 1999; 17: 1125--’ 33.
42. Sarzani R, Dessi-Fulgheri P, Salvi F, et al. A novel promoter variant of the natriuretic peptide clearance receptor gene is associated with lower atrial natriuretic peptide and higher blood pressure in obese hypertensives. J Hypertens 1999; 17: 1301-5.
43. Sclmlieder RE, GatzkaC, Schachinger H, etal. Obesity as a determinant to antihypertensive treatment. Br Med J 1993; 307: 537-40.
44. Schmieder RE, MesserliFH. Does obesityinfluence early target organ damage j$ hypertensive patients? Circulation 1993; 87: 1482—8.
45. Sliarma AM, Pischon T, Hardt S, et al. Hypothesis: beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 2001;37:250-4.
46. Shek EW, Kim PK, Hall JE. Adrenergic blockade prevents leptin-induced hypertension. FASEB 1999; J13: A456.
47. Simon G, Devereux RB, Roman MJ Relation of obesity and gender to left ventricular hypertrophy in nomrotensive and hypertensive adults. Hypertension, 1994, 23:600-6
48. Stepniakowski KT, Goodfriend ТЕ» Egan BM Fatty acids entrance vascular a-adrenergic sensitivity. Hypertension 1995; 25: 774—8.
49. Stem JS, Gades MD, Wheeldon CM, et al. Calorie restriction in obesity: prevention of kidney disease in rodents. J Nutrit 2001; 131: 913S-7.
50. Sundquist J, Winkeby MA, Pudaric S. Cardiovascular disease risk factors among older black, Mexican-American, and white women and men: an analysis of NHANES III, 1988-1994. J Am Geriatr Soc 2001; 49:109-16.
51. Tuck ML, Sowers J, Donrfield L, et al. The effect of weight reduction on blood pressure plasma renin activity and plasma aldosterone level in obese patients. N Engl J Med 1981; 304:930-3.
52. VanHeek M, Conrptonr DS, France CF, et al. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest 1997; 99: 385-90.
53. Wfeyer C, Pratley RE, Snitker, et al. Ethnic differences in insulinenria and sympathetic tone as links between obesity and blood pressure. Hypertension 2000; 36:531-7.
54. Wofford MR, Anderson DC, Brown CA, et al. Antihypertensive effect of alpha and beta adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 2001; 14: 694—8.
55. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ranripril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145 -53.
56. Zhang R, Reisin E. Obesity-hypertension: the effects on cardiovascular and renal systems. Am J Hypertens 2000; 13: 1308—14.
57. Беленков Ю.Н., Чазова I ЕЕ.. Мычка В.Б. Многоцентровое рандомизированное открытое исследование по изучению эффективности изменения образа жизни и терапии ингибитором АПФ (квинаприЯом) у больных ожирением и артериальной гипертонией (ЭКО). Артер типерт 2003; 9(6): 196-9.
58. Мычка В.Б., Чазова И.Е. Российская доказательная медицина — программа МИНОТАВР: преимущества ретардной формы индапамида при лечении метаболического синдрома. Cons med 2006; 8(5): 46-50.
59. Недогода С.В., Барыкина И.Н., Брель УА., Чаляби ТА. Возможность коррекции Равелом СР факторов риска при артериальной гипертензии на фоне ожирения. Cons med. Приложение “Системные гипертензии” 2007; 1:14—8.
60. Чазова И.Е., Мычка В.Б. Открытая, многоцентровая, рандомизированная, научно-практическая программа МИНОТАВР: промежуточный анализ результатов. Кардиоваск тер профил 2006;2:81-8.
Рецензия
Для цитирования:
Недогода С.В., Барыкина И.Н., Чаляби Т.А., Бутрина Л.В., Брель У.А., Мазина Г.В., Подольская Е.А. Ожирение и артериальная гипертензия. Часть II: особенности антигипертензивной терапии при ожирении. Кардиоваскулярная терапия и профилактика. 2009;8(1):88-98.
For citation:
Nedogoda S.V., Barykina I.N., Chalyabi T.A., Butrina L.V., Brel U.A., Mazina G.V., Podolskaya E.A. Obesity and arterial hypertension. Part II: features of antihypertensive therapy in obese patients. Cardiovascular Therapy and Prevention. 2009;8(1):88-98. (In Russ.)
Просмотров:
3037
Послать статью по эл. почте 
